Article
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%
Rating:
0.0
Views:
68
Likes:
1
Library:
1
A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value